595 results on '"Welsh, James W"'
Search Results
152. Radiotherapy Augments Pembrolizumab Responses and Outcomes in Metastatic Non-Small Cell Lung Cancer: Pooled Analysis of Two Randomized Trials
153. Outcomes of re-irradiation for brain recurrence after prophylactic or therapeutic whole-brain irradiation for small cell lung Cancer: a retrospective analysis
154. Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti–PD1-Resistant Lung Tumor Model
155. Anti-glucocorticoid-induced Tumor Necrosis Factor–Related Protein (GITR) Therapy Overcomes Radiation-Induced Treg Immunosuppression and Drives Abscopal Effects
156. Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer
157. Barriers to Combined-Modality Therapy for Limited-Stage Small Cell Lung Cancer
158. Safety of Combined Immunotherapy and Thoracic Radiation Therapy: Analysis of 3 Single-Institutional Phase I/II Trials
159. Overview of ongoing clinical trials investigating combined radiotherapy and immunotherapy
160. Radiation therapy and immunotherapy: what is the optimal timing or sequencing?
161. Ionizing Radiation as a Carcinogen
162. Combining radiation plus immunotherapy to improve systemic immune response
163. Development of an Immune-Pathology Informed Radiomics Model for Non-Small Cell Lung Cancer
164. MolecularMatch LAB Integrates Knowledgebases for Collaborative Clinical Interpretation of Variation in Cancer
165. Abstract 1017: Lipid metabolic reprogramming drives resistance to PD1 blockage
166. Stereotactic Ablative Radiation Therapy is Highly Safe and Effective for Elderly Patients With Early-stage Non-Small Cell Lung Cancer
167. Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells
168. Analysis of Factors Affecting Successful Clinical Trial Enrollment in the Context of Three Prospective, Randomized, Controlled Trials
169. Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy
170. Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective Phase I/II Trial
171. Phase I Trial: SABR and Ipilimumab—Response
172. Abstract 569: MicroRNA-mediated resistance to anti-PD1 therapy in lung cancer
173. Single Nucleotide Polymorphisms in CBLB, a Regulator of T-Cell Response, Predict Radiation Pneumonitis and Outcomes After Definitive Radiotherapy for Non–Small-Cell Lung Cancer
174. Preclinical Rationale and Clinical Considerations for Radiotherapy Plus Immunotherapy
175. Racial and Insurance-related Disparities in Delivery of Immunotherapy-type Compounds in the United States.
176. Twice-daily Thoracic Radiotherapy for Limited-stage Small-cell Lung Cancer Does Not Increase the Incidence of Acute Severe Esophagitis.
177. Cost Analysis of PET/CT Versus CT as Surveillance for Stage III Non-Small-Cell Lung Cancer After Definitive Radiation Therapy.
178. Radiation and Anti-Cancer Vaccines: A Winning Combination.
179. Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer
180. PDL1 Regulation by p53 via miR-34
181. Strategies for combining immunotherapy with radiation for anticancer therapy
182. Abstract 2875: p53 regulation of PDL1 is mediated through miR-34a
183. Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer
184. Author's view: radiation and immunotherapy as systemic therapy for solid tumors
185. 42 - MolecularMatch LAB Integrates Knowledgebases for Collaborative Clinical Interpretation of Variation in Cancer
186. Incidence of Second Malignancy after Successful Treatment of Limited-Stage Small-Cell Lung Cancer and Its Effects on Survival.
187. Intensity-Modulated Radiotherapy versus 3-Dimensional Conformal Radiotherapy Strategies for Locally Advanced Non-Small-Cell Lung Cancer
188. Hemithoracic Intensity Modulated Radiation Therapy After Pleurectomy/Decortication for Malignant Pleural Mesothelioma: Toxicity, Patterns of Failure, and a Matched Survival Analysis
189. Galectin-1 and Immune Suppression during Radiotherapy
190. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression
191. Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?
192. Stereotactic ablative radiotherapy (SABR) using 70Gy in 10 fractions for non-small cell lung cancer: Exploration of clinical indications
193. Lymphopenia Association With Gross Tumor Volume and Lung V5 and Its Effects on Non-Small Cell Lung Cancer Patient Outcomes
194. Su1971 Is a Repeat Endoscopy (EGD) Necessary When Referred for Staging of Newly Diagnosed Esophageal Cancer?: A Comparison of Cancer Specialty Institution (CSI) With Other Institutions (Osf)
195. Translational Research and Immunotherapy in Lung Cancer.
196. Progress in the management of limited-stage small cell lung cancer
197. Factors Associated with Local–Regional Failure After Definitive Chemoradiation for Locally Advanced Esophageal Cancer
198. Reply to V.R. Bhatt et al and M.C. Chamberlain
199. The Influence of Histopathologic Tumor Viability on Long-term Survival and Recurrence Rates Following Neoadjuvant Therapy for Esophageal Adenocarcinoma
200. Su1539 Is Dilation Necessary to Complete EUS Staging for Esophageal Cancer?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.